Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations

Lopez, Salvatore

356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations

Sunday, March 29, 2015: 7:00 AM

Salon C-D (Hilton Chicago)

S. Lopez¹, S. Bellone², J. D. Black², C. L. Schwab², D. P. English², C. Terranova¹, P. E. Schwartz², T. J. Rutherford², R. Angioli¹ and A. Santin²
¹University Campus Bio-Medico of Rome, Rome, Italy, ²Yale University School of Medicine, New Haven, CT

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations

356 Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations

356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations